Evaluation of anticoagulation re-initiation practices following reversal of factor Xa inhibitors with andexanet alfa or 4F-PCC in patients with major bleeding events
Background: Both andexanet alfa and 4F-PCC reversal strategies have been associated with thrombotic events. It remains unclear whether the risk is associated with the reversal agent or the lack of re-initiation of anticoagulation. Objective: The aim of this study was to describe anticoagulant (AC) r...
Main Authors: | Awatif Hafiz, Alshaya Abdulrahman I, Katelyn W. Sylvester, Jean M. Connors, Jessica Rimsans |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-12-01
|
Series: | Thrombosis Update |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666572721000456 |
Similar Items
-
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
by: Kaatz S, et al.
Published: (2017-09-01) -
Reversal of direct oral anticoagulants
by: Almegren M
Published: (2017-07-01) -
Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro<sup>®</sup> Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients
by: Daniel Oberladstätter, et al.
Published: (2021-08-01) -
Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
by: Stephanie A. Kustos, et al.
Published: (2019-10-01) -
Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update
by: Shagun B Shah, et al.
Published: (2019-01-01)